PMID- 29442014
OWN - NLM
STAT- MEDLINE
DCOM- 20180829
LR  - 20180829
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 73
IP  - 2
DP  - 2018 Feb 1
TI  - Improvement of treatment outcomes after implementation of comprehensive 
      pharmaceutical care in breast cancer patients receiving everolimus and 
      exemestane.
PG  - 110-114
LID - 10.1691/ph.2018.7837 [doi]
AB  - Combination therapy with everolimus and an aromatase inhibitor such as exemestane 
      is an effective treatment option for advanced or recurrent breast cancer. 
      However, the therapy is often limited because of the occurrence of severe adverse 
      events (AEs), including oral mucositis, interstitial lung disease, diarrhea, and 
      rash. Therefore, early management of AEs is extremely important to obtain maximum 
      treatment outcome. We investigated here the effects of comprehensive 
      pharmaceutical care for prevention of severe AEs on patient's quality-of-life 
      (QOL) and continuation of therapy. QOL was assessed every month based on the 
      five-level version of EuroQol-5-Dimension (EQ-5D-5L). AEs were graded according 
      to the Common Terminology Criteria for Adverse Events (ver 4.0). Implementation 
      of comprehensive pharmaceutical care remarkably reduced the incidence of severe 
      oral mucositis as compared with those without such interventions. EQ-5D-5L health 
      states were almost constant during 6 months after intervention, ranging from 
      0.850 to 0.889. Median time to treatment failure (TTF) was significantly longer 
      after intervention than before [224.0 days, 95% confidence interval (CI): 117-331 
      days versus 34 days, 21-47 days, hazard ratio (HR): 0.027, 95% CI: 0.005 - 0.154, 
      p<0.001]. These findings suggest that our comprehensive pharmaceutical care is 
      highly effective for enhancing treatment outcome by maintaining patient's QOL.
FAU - Todo, M
AU  - Todo M
FAU - Ueda, S
AU  - Ueda S
FAU - Osaki, S
AU  - Osaki S
FAU - Sugitani, I
AU  - Sugitani I
FAU - Takahashi, T
AU  - Takahashi T
FAU - Takahashi, M
AU  - Takahashi M
FAU - Makabe, H
AU  - Makabe H
FAU - Saeki, T
AU  - Saeki T
FAU - Itoh, Y
AU  - Itoh Y
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Androstadienes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Aromatase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - NY22HMQ4BX (exemestane)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Androstadienes/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Aromatase Inhibitors/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/psychology
MH  - Disease-Free Survival
MH  - Everolimus/*therapeutic use
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Patient Compliance
MH  - *Pharmaceutical Services
MH  - Postmenopause
MH  - Quality of Life
MH  - Stomatitis/chemically induced/therapy
MH  - Treatment Failure
EDAT- 2018/02/15 06:00
MHDA- 2018/08/30 06:00
CRDT- 2018/02/15 06:00
PHST- 2018/02/15 06:00 [entrez]
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2018/08/30 06:00 [medline]
AID - 10.1691/ph.2018.7837 [doi]
PST - ppublish
SO  - Pharmazie. 2018 Feb 1;73(2):110-114. doi: 10.1691/ph.2018.7837.